Adage Capital Partners
SNDX icon

Adage Capital Partners’s Syndax Pharmaceuticals SNDX Stock Holding History

Adage Capital Partners’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,311,963
Closed -$51M – 1007
2025
Q3 		$51M Buy
3,311,963
+1,879,523
+131% +$24.6M 0.08% 239
2025
Q2 		$13.4M Buy
1,432,440
+800,800
+127% +$8.81M 0.02% 552
2025
Q1 		$7.76M Buy
631,640
+9,800
+2% +$138K 0.01% 635
2024
Q4 		$8.22M Sell
621,840
-195,760
-24% -$3.35M 0.01% 652
2024
Q3 		$15.7M Sell
817,600
-42,400
-5% -$876K 0.03% 510
2024
Q2 		$17.7M Sell
860,000
-40,000
-4% -$837K 0.03% 467
2024
Q1 		$21.4M Hold
900,000
– – 0.04% 430
2023
Q4 		$19.4M Sell
900,000
-100,000
-10% -$1.54M 0.04% 428
2023
Q3 		$14.5M Buy
1,000,000
+75,000
+8% +$1.42M 0.03% 481
2023
Q2 		$19.4M Buy
925,000
+135,000
+17% +$2.81M 0.04% 414
2023
Q1 		$16.7M Sell
790,000
-150,000
-16% -$3.73M 0.04% 480
2022
Q4 		$23.9M Sell
940,000
-310,000
-25% -$7.23M 0.06% 375
2022
Q3 		$30M Buy
1,250,000
+12,700
+1% +$285K 0.07% 290
2022
Q2 		$23.8M Buy
1,237,300
+158,659
+15% +$2.64M 0.05% 368
2022
Q1 		$18.7M Sell
1,078,641
-121,359
-10% -$2.04M 0.04% 477
2021
Q4 		$26.3M Sell
1,200,000
-1,666,272
-58% -$30.8M 0.05% 385
2021
Q3 		$54.8M Buy
2,866,272
+375,000
+15% +$6.25M 0.11% 198
2021
Q2 		$42.8M Buy
2,491,272
+741,272
+42% +$13.6M 0.08% 248
2021
Q1 		$39.1M Sell
1,750,000
-80,439
-4% -$1.82M 0.08% 264
2020
Q4 		$40.7M Buy
1,830,439
+130,439
+8% +$2.71M 0.09% 243
2020
Q3 		$25.1M Buy
1,700,000
+650,000
+62% +$9.91M 0.06% 330
2020
Q2 		$15.6M Buy
1,050,000
+50,000
+5% +$762K 0.04% 448
2020
Q1 		$11M Sell
1,000,000
-250,000
-20% -$2.35M 0.03% 452
2019
Q4 		$11M Hold
1,250,000
– – 0.03% 524
2019
Q3 		$9.34M Sell
1,250,000
-225,000
-15% -$2.05M 0.02% 528
2019
Q2 		$13.7M Sell
1,475,000
-75,000
-5% -$547K 0.03% 449
2019
Q1 		$8.14M Buy
+1,550,000
New +$8.84M 0.02% 553

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Adage Capital Partners's SNDX Position: Q4 2025 in Review

Adage Capital Partners sold out of Syndax Pharmaceuticals (SNDX) in Q4 2025, closing a stake of 3,311,963 shares — an estimated $51M sold.

Adage Capital Partners first reported a position in SNDX in Q1 2019 and held it in 27 quarters. The position peaked at $54.8M in Q3 2021. 229 funds tracked by Wall St. Rank hold SNDX as of Q4 2025.

  • Adage Capital Partners reported no remaining Syndax Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Adage Capital Partners sold 3,311,963 Syndax Pharmaceuticals shares in Q4 2025, an estimated $51M.
  • Adage Capital Partners first reported a position in Syndax Pharmaceuticals in Q1 2019 and held it in 27 quarters.
  • Adage Capital Partners's Syndax Pharmaceuticals position peaked at $54.8M in Q3 2021.
  • 229 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2025.

Based on Adage Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.